Radiopharmacy

The radiopharmacy unit of the department of nuclear medicine LMU in Großhadern offers the opportunity to produce radioactive drugs in GMP (Good Manufacturing Practice) quality according to current guidelines for radiation protection and regulations for medicinal products. Built in 2013, the production site with an in-house cyclotron and integrated laboratories is operated in cooperation with AAA Munich GmbH within the framework of a Public-Private-Partnership (PPP) and is the basis for providing new biomarkers for diagnostics and new therapeutic agents for the individualized therapy of patients on demand and in highest quality. This ensures patient care on a highest possible standard. The radiopharmacy unit offers best conditions for clinical studies, preclinical and radiopharmaceutical fundamental research.
Among others, the following tracers are produced for clinical and preclinical investigations:

• ⁶⁸Ga-PSMA, ¹⁸F-PSMA, ¹⁷⁷Lu-PSMA und ²²⁵Ac-PSMA
• ⁶⁸Ga-TATE, ⁶⁸Ga-TOC und ¹⁷⁷Lu-TATE
• ¹¹C-Flumazenil
• ¹⁸F-FLT
• ¹⁸F-ML10
• ¹⁸F-DMFP und ¹⁸F-FP
• ¹⁸F-MPPF
• ¹⁸F-GE180
• ¹⁸F-Flutemetamol
• ¹⁸F-Florbetaben
• ¹⁸F-THK5117 und ¹⁸F-GE216 (¹⁸F-THK5351)
• ¹⁸F-UCB-H

Different platforms from GE Healthcare, Scintomics, Elysia-Raytest, Comecer and Trasis are available for tracer production.

GMP-Laboratories classified in C and B